Drug intelligence / Profile preview

KPL-387

Development stage: Phase 3
Lead developer: Kiniksa Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

KPL-387 is a fully human immunoglobulin G2 (IgG2) monoclonal antibody developed by Kiniksa Pharmaceuticals. It binds to the human interleukin-1 receptor 1 (IL-1R1), thereby inhibiting the signaling activity of both interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). This mechanism blocks the inflammatory pathway mediated by these cytokines. The drug is being developed as a potential treatment for recurrent pericarditis, with a target profile of monthly subcutaneous dosing in a liquid formulation, aiming to improve patient adherence and convenience compared to existing therapies[3][8][9].

Targets

IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on KPL-387.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KPL-387.

Explore the full profile